Hasil Pencarian (1)
small molecule | CAS: 1420477-60-6
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acala…
Kategori:
Acids, CarbocyclicAmidesAntineoplastic Agents
+19
Target Protein:
Tyrosine-protein kinase BTK
Waktu ParuhAfter administering…
Vol. DistribusiThe mean steady-sta…
KlirensAcalabrutinib's mea…
Genetik
-